(Q38095386)

28 August 2017

title

Dasatinib: a guide to its use in chronic myeloid leukemia in the EU. (English)

1 reference

Katherine A Lyseng-Williamson

28 August 2017

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

28 August 2017

1

Gillian M Keating

1 reference

28 August 2017

Paul L McCormack

3

1 reference

28 August 2017

Susan J Keam

series ordinal

4

1 reference

28 August 2017

publication date

1 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

275-279

1 reference

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Dasatinib: is it all in the dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0024-7

10.1007/S40259-013-0024-7

21 January 2018

Identifiers

DOI

1 reference

release_3zwnb4bnirf4diytdxrqf4vuka

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3zwnb4bnirf4diytdxrqf4vuka

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference